Max India Q2 FY27 Results: Loss Trend and Valuation Explained

Max India Q2 results for the September 2026 quarter are the next data point for this Max Group holding company's shareholders. Track the latest Max India Ltd. share price on Univest as the company approaches its Q2 FY27 announcement. This Max India Q2 results preview relies only on already-reported historical numbers, given the company's holding-company structure.

Max India Q2 Results Date

No official Max India Q2 results date has been announced yet. Listed holding companies in India typically report their September-quarter numbers in the October to November window, and Max India Q2 results are expected to follow that same broad calendar once the board confirms a date. Investors should check the company's own exchange filings for the confirmed Max India Q2 results date.

Max India Q2 Results Expectations

Max India Q2 results expectations need to be set with a clear understanding of what this company's reported P&L actually captures. Max India is a holding and investment company within the Max Group, with stakes in Max Healthcare, Antara Senior Living, and Max Life, and its own screener note states plainly that the reported quarterly P&L has been persistently loss-making and does not reflect the underlying value of its investment portfolio. Over the last five quarters, operating margin has ranged from -22.73% to -83.72%, and net losses have ranged from Rs19 crore to Rs43 crore. Max India Q2 results expectations should be built around that loss-making operating pattern, using the historical range as context rather than assuming any specific number for the September quarter.

Also read – Dabur India Q2 Results FY27 Preview

Max India Q2 Results Preview: Previous Quarter (Q1 FY27, Jun26)

The quarter right before Max India Q2 results, Q1 FY27 ended June 2026, showed revenue of Rs60 crore, an operating loss of Rs34 crore, an operating margin of -56.67%, and a net loss of Rs36 crore. This followed a smaller net loss of Rs19 crore in the Mar26 quarter, so the loss widened again in Jun26, and this is the sequential base Max India Q2 results will be measured against.

Q2 FY26 (Sep25): The Base Quarter for Comparison

Year-on-year comparisons for Max India Q2 results will use the Q2 FY26 quarter ended September 2025 as the reference point. In Sep25, Max India reported revenue of Rs45 crore, an operating loss of Rs31 crore, an operating margin of -68.89%, and a net loss of Rs34 crore. That Sep25 quarter was also loss-making, consistent with every other quarter in the five-quarter dataset, and it is the base against which Max India Q2 results for Sep26 will be compared.

Recent Trend: Jun25 Through Jun26

The five-quarter trend ahead of Max India Q2 results shows core operations that have been loss-making in every single quarter on record. Revenue moved from Rs37 crore in Jun25, to Rs45 crore in Sep25, Rs43 crore in Dec25, Rs66 crore in Mar26, and Rs60 crore in Jun26. Operating margin across those five quarters read -75.68%, -68.89%, -83.72%, -22.73% and -56.67%, while net profit was a loss of Rs26 crore, a loss of Rs34 crore, a loss of Rs43 crore, a loss of Rs19 crore, and a loss of Rs36 crore. Stated plainly, core operations at Max India have been loss-making across all five quarters in this data set, and nothing in the historical numbers points to a specific turnaround date, so that pattern should not be extrapolated forward when thinking about Max India Q2 results.

Key Factors to Watch Around Max India Q2 Results

A few factors matter most for Max India Q2 results. First, because Max India functions as a holding and investment vehicle for stakes in Max Healthcare, Antara Senior Living, and Max Life, its standalone reported revenue and operating loss do not capture the value or performance of those underlying investments, a distinction that matters when reading Max India Q2 results. Second, the operating loss has ranged widely, from -22.73% in Mar26 to -83.72% in Dec25, so Max India Q2 results could plausibly fall anywhere within that already-demonstrated range based on history alone. Third, revenue itself has moved between Rs37 crore and Rs66 crore over the last five quarters, and that range is the relevant historical backdrop for Max India Q2 results. Keeping this range in view is the most grounded way to approach the Max India Q2 results announcement.

Max India Q2 Results: Valuation Snapshot

On valuation, Max India trades at a CMP of Rs149.25, against a 52-week high of Rs241.57 and a 52-week low of Rs120.0. Both PE and EPS are marked not meaningful on a trailing loss, price-to-book is 1.92x against a book value of Rs77.7, and return on equity is -32.8%. Debt-to-equity is 0.23, the company pays no dividend, and market capitalisation is Rs842 crore. The 50-day moving average is Rs158.12 and the 200-day moving average is Rs161.59, with an RSI of 51.75. These figures stay unchanged until Max India Q2 results are formally reported.

Also read – Dalmia Bharat Q2 Results FY27 Preview

What to Watch When Max India Q2 Results Are Announced

When Max India Q2 results are announced, the key items to check are whether the operating loss narrows or widens relative to the -56.67% margin seen in Q1 FY27 and the -68.89% margin seen in Sep25, how revenue compares with the Rs60 crore Q1 FY27 base, and any management commentary on the underlying value of the Max Healthcare, Antara Senior Living, and Max Life stakes, since Max India Q2 results reflect only the standalone reported P&L and not the value of that investment portfolio.

Want to follow Max India alongside the wider Max Group? Open a free Univest demat account to track the stock through results season.

Conclusion

Max India Q2 results for the September 2026 quarter have not yet been reported, and no specific date or figure should be assumed in advance. The historical data through Jun26 shows a holding company whose core reported operations have been loss-making in every one of the last five quarters, with operating margin ranging from -22.73% to -83.72% and net losses between Rs19 crore and Rs43 crore, a pattern the company's own screener note says does not reflect the value of its underlying investment stakes. That plain, loss-making track record, without any speculation on a turnaround, is the context to carry into Max India Q2 results.

Track Max India and the broader Max Group ecosystem by choosing to open a demat account with Univest today.

Set up your account ahead of results season. Start your Univest demat account here.

This article is for informational purposes only and does not constitute investment advice, a recommendation, or a solicitation to buy or sell any security. Data points cited are drawn from historical, already-reported financial results and publicly available market data, and figures for the Q2 FY27 (September 2026) quarter had not been announced as of the date of writing. Investments in securities are subject to market risk; please read all scheme and company-related documents carefully and consult a SEBI-registered investment or research advisor before making any investment decision. Univest Research Services is a SEBI-registered Research Analyst, registration number INH000013776.

When will Max India Q2 results be announced?

Ans. No official Max India Q2 results date has been announced yet. Listed holding companies in India typically report their September-quarter numbers in the October to November window, and Max India is expected to follow that same broad calendar.

Has Max India's core business been profitable recently?

Ans. No. Core operations at Max India have been loss-making across all five quarters on record, with operating margin ranging from -22.73% to -83.72% and net losses between Rs19 crore and Rs43 crore, most recently a net loss of Rs36 crore in Q1 FY27.

What was Max India's performance in Q1 FY27?

Ans. In Q1 FY27 (Jun26), Max India reported revenue of Rs60 crore, an operating loss of Rs34 crore, an operating margin of -56.67%, and a net loss of Rs36 crore.

What is Max India's valuation ahead of Q2 results?

Ans. Max India trades at a CMP of Rs149.25, with both PE and EPS marked not meaningful on a trailing loss, a price-to-book of 1.92x, and a return on equity of -32.8%.